Joao M. P.
- Country
- Portugal
- Department
- Centro de Investigação e Inovação
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Phase 3 Randomized Study of Amivantamab, Lazertinib, and Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC Post-Osimertinib Failure
- Phase 3 Multicenter Randomized Open-label Study of Ifinatamab Deruxtecan Versus Physician's Choice in Relapsed Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 78 of 251 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of non-small cell lung cancer (NSCLC), with particular emphasis on advanced stages of the disease including locally advanced and metastatic conditions.
- Advanced NSCLC Management
- Metastatic Disease Treatment
Molecular Expertise
The investigator has developed specific expertise in treating lung cancers with EGFR mutations, particularly focusing on cases involving Exon 19 deletions and Exon 21 L858R substitutions.
- EGFR-Mutated Cancer Treatment
- Targeted Therapy Approaches
Treatment Innovation
This specialist works with innovative therapeutic combinations including targeted therapies and platinum-based chemotherapy for patients who have progressed after previous treatments.
- Combination Therapy Development
- Treatment Resistance Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.